BiondVax Pharmaceuticals Ltd. (BVXV) |
|
2.6 0.01 (0.39%)
|
02-02 15:18 |
|
Open: |
2.55 |
Pre. Close: |
2.59 |
|
High:
|
2.6497 |
Low:
|
2.545 |
|
Volume:
|
68,943 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 3:10:20 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.65 One year: 4.2 |
| Support: |
Support1: 2.36 Support2: 1.97 |
| Resistance: |
Resistance1: 3.13 Resistance2: 3.59 |
| Pivot: |
2.71  |
| Moving Average: |
MA(5): 2.6 MA(20): 2.74
MA(100): 6.75 MA(250): 10.36 |
| MACD: |
MACD(12,26): -0.7  Signal(9): -0.9 |
| Stochastic oscillator: |
%K(14,3): 32.7 %D(3): 30.7 |
| RSI: |
RSI(14): 31.1 |
| 52-week: |
High: 22.89 Low: 1.14 |
| Average Vol(K): |
3-Month: 162 (K) 10-Days: 152 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BVXV ] has closed above bottom band by 29.6%. Bollinger Bands are 86.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.65 - 2.67 |
2.67 - 2.68 |
|
Low:
|
2.49 - 2.51 |
2.51 - 2.52 |
|
Close:
|
2.56 - 2.59 |
2.59 - 2.61 |
|
Company Description |
|
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel. |
Headline News |
Thu, 02 Feb 2023
BiondVax Presenting at BIO CEO & Investor Conference - The Bakersfield Californian
Thu, 02 Feb 2023
BiondVax Presenting at BIO CEO & Investor Conference - BiondVax Pharmaceuticals (NASDAQ:BVXV) - Benzinga
Wed, 01 Feb 2023
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by ... - Armenian Reporter
Tue, 31 Jan 2023
Is Biondvax Pharmaceuticals Ltd - ADR (BVXV) a Winner in the Biotechnology Industry? - InvestorsObserver
Mon, 30 Jan 2023
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports ... - StreetInsider.com
Fri, 27 Jan 2023
Do Traders Think Biondvax Pharmaceuticals Ltd - ADR (BVXV) Can Turn Around Friday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
27.7 (%) |
|
% Held by Institutions
|
13.2 (%) |
|
Shares Short
|
56 (K) |
|
Shares Short P.Month
|
38 (K) |
Stock Financials |
|
EPS
|
-2.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.02 |
|
EPS Est Next Year
|
-0.02 |
|
Book Value (p.s.)
|
0.61 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-21 |
|
Return on Equity (ttm)
|
-432.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.14 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.28 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
